Impact of renal denervation on quality of life how does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?
Adherence
Catheter-based renal sympathetic denervation
Clinical Trial
Humans
Hypertension
Preference
Quality of Life
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
11 Apr 2024
11 Apr 2024
Historique:
received:
27
02
2024
accepted:
22
03
2024
revised:
20
03
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
11
4
2024
Statut:
aheadofprint
Résumé
The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.
Identifiants
pubmed: 38605140
doi: 10.1038/s41440-024-01679-7
pii: 10.1038/s41440-024-01679-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Références
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.
pubmed: 24678939
doi: 10.1056/NEJMoa1402670
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
pubmed: 23817082
doi: 10.1097/01.hjh.0000431740.32696.cc
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.
pubmed: 30165516
doi: 10.1093/eurheartj/ehy339
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335–45.
pubmed: 29803590
doi: 10.1016/S0140-6736(18)31082-1
Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329:651–61.
pubmed: 36853250
pmcid: 9975904
doi: 10.1001/jama.2023.0713
Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70.
pubmed: 28859944
doi: 10.1016/S0140-6736(17)32281-X
Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–55.
pubmed: 29803589
doi: 10.1016/S0140-6736(18)30951-6
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.
pubmed: 34010611
doi: 10.1016/S0140-6736(21)00788-1
Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46:280–8.
pubmed: 36241705
doi: 10.1038/s41440-022-01042-8
Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45:221–31.
pubmed: 34654905
doi: 10.1038/s41440-021-00754-7
Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.
pubmed: 37345492
doi: 10.1097/HJH.0000000000003480
Schmieder RE, Jumar A, Fronk EM, Alexandre AF, Bramlage P. Quality of life and emotional impact of a fixed-dose combination of antihypertensive drugs in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2017;19:126–34.
pubmed: 27785884
doi: 10.1111/jch.12936
Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, et al. The effects of antihypertensive therapy on the quality of life. N. Engl J Med. 1986;314:1657–64.
pubmed: 3520318
doi: 10.1056/NEJM198606263142602
Bremner AD. Antihypertensive medication and quality of life–silent treatment of a silent killer? Cardiovasc Drugs Ther. 2002;16:353–64.
pubmed: 12652105
doi: 10.1023/A:1021790112182
Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens. 2003;21:1283–9.
pubmed: 12817174
doi: 10.1097/00004872-200307000-00015
Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens Res. 2003;26:159–62.
pubmed: 12627876
doi: 10.1291/hypres.26.159
Yoshida K, Matsuoka H, Omae T, Fujii J. Patient-hospital relationship and quality of life in elderly patients with hypertension. Hypertens Res. 1995;18:77–83.
pubmed: 7584915
doi: 10.1291/hypres.18.77
Kario K, Kai H, Nanto S, Yokoi H. Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation. Hypertens Res. 2023;46:2044–7.
pubmed: 37264122
pmcid: 10404509
doi: 10.1038/s41440-023-01333-8
Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076–80.
pubmed: 21502568
doi: 10.1161/HYPERTENSIONAHA.111.170308
Kario K, Okura A, Okawara Y, Tomitani N, Ikemoto T, Hoshide S. Impact of introducing catheter-based renal denervation into Japan for hypertension management: Estimation of number of target patients and clinical relevance of ambulatory blood pressure reduction. Curr Hypertens Rev. 2016;12:156–63.
Okamura K, Shirai K, Okuda T, Urata H. The prevalence of Japanese outpatients with hypertension who meet the definition of treatment resistant hypertension and are eligible for enrolment in clinical trials of endovascular ultrasound renal denervation. Intern Med. 2018;57:1–12.
pubmed: 29033430
doi: 10.2169/internalmedicine.9059-17
Okamura K, Yano Y, Takamiya Y, Shirai K, Urata H. Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): “Issues with hypertension studies in real-world practice”. Clin Exp Hypertens. 2020;42:438–48.
pubmed: 31756122
doi: 10.1080/10641963.2019.1693586
Okamura K, Shirai K, Miyazaki M, Okuda T, Takamiya Y, Goto M, et al. Investigation of a dipeptidyl peptidase-4 inhibitor/thiazolidinedione combination drug for patients with type 2 diabetes and poor glycemic control: difficulty with patient enrollment. J Clin Med Res. 2019;11:89–97.
pubmed: 30701000
pmcid: 6340677
doi: 10.14740/jocmr3558
Okamura K, Shirai K, Totake N, Okuda T, Urata H. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine. Clin Exp Hypertens. 2018;40:99–106.
pubmed: 28692311
doi: 10.1080/10641963.2017.1334798
Okamura K, Okuda T, Kumagai N, Mitsutake R, Urata H. CHAT-E i: antihypertensive effect and safety of a candesartan/hydrochlorothiazide combination in patients with uncontrolled hypertension. Therapeutic Res. 2015;36:439–48.
Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, et al. Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure at 6 months following medication escalation: The RADIANCE Clinical Trial Program. Circulation. 2024;149:747-759.
Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan: where are we now? Circ J. 2013;77:2226–31.
pubmed: 23902998
doi: 10.1253/circj.CJ-13-0847
Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens. 2018;31:1156–63.
pubmed: 30010694
doi: 10.1093/ajh/hpy108
Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45:232–40.
pubmed: 34657136
doi: 10.1038/s41440-021-00760-9
Zhang Z, Zhang X, Ye R, Li X, Chen X. Patient preference for renal denervation therapy in hypertension: a cross-sectional survey in Chengdu, China. Hypertens Res. 2022;45:954–61.
pubmed: 35388177
doi: 10.1038/s41440-022-00912-5
Schmieder RE, Hogerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108:1331–42.
pubmed: 30941492
doi: 10.1007/s00392-019-01468-0
Kresoja KP, Rommel KP, Fengler K, von Roeder M, Besler C, Lucke C, et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2021;14:e007421.
pubmed: 33706547
doi: 10.1161/CIRCHEARTFAILURE.120.007421
Kase M, Fujiki S, Kashimura T, Okura Y, Kodera K, Watanabe H, et al. Relationship between medical therapy, long-term care insurance, and comorbidity in elderly patients with heart failure with systolic dysfunction. Circ J. 2023;87:1130–7.
pubmed: 36928271
doi: 10.1253/circj.CJ-22-0830
Kewcharoen J, Vutthikraivit W, Rattanawong P, Prasitlumkum N, Akoum NW, Bunch TJ, et al. Renal sympathetic denervation in addition to pulmonary vein isolation reduces the recurrence rate of atrial fibrillation: an updated meta-analysis of randomized control trials. J Inter Card Electrophysiol. 2021;60:459–67.
doi: 10.1007/s10840-020-00748-4
Heradien M, Mahfoud F, Greyling C, Lauder L, van der Bijl P, Hettrick DA, et al. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Heart Rhythm. 2022;19:1765–73.
pubmed: 35781044
doi: 10.1016/j.hrthm.2022.06.031
Hawson J, Harmer JA, Cowan M, Virk S, Campbell T, Bennett RG, et al. Renal denervation for the management of refractory ventricular arrhythmias: a systematic review. JACC Clin Electrophysiol 2021;7:100–8.
pubmed: 33478701
doi: 10.1016/j.jacep.2020.07.019
Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive sleep apnea-induced neurogenic nocturnal hypertension: a potential role of renal denervation? Hypertension. 2021;77:1047–60.
pubmed: 33641363
doi: 10.1161/HYPERTENSIONAHA.120.16378
Kou C, Zhao X, Lin X, Fan X, Wang Q, Yu J. Effect of different treatments for obstructive sleep apnoea on blood pressure. J Hypertens. 2022;40:1071–84.
pubmed: 35703874
doi: 10.1097/HJH.0000000000003131
Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder RE, Tsioufis K, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol. 2021;77:2909–19.
pubmed: 33957242
doi: 10.1016/j.jacc.2021.04.044
Satoh M, Kikuya M, Hara A, Ohkubo T, Mori T, Metoki H, et al. Aldosterone-to-renin ratio and home blood pressure in subjects with higher and lower sodium intake: the Ohasama study. Hypertens Res. 2011;34:361–6.
pubmed: 21124331
doi: 10.1038/hr.2010.236
Liu Y, Zhu B, Zhu L, Zhao L, Fan Z, Ding D, et al. Thirty-six-month results of laparoscopic-based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosterone-producing adenoma. J Clin Hypertens (Greenwich). 2021;23:946–53.
pubmed: 33591620
doi: 10.1111/jch.14223
Gosse P, Sentilhes L, Boulestreau R, Doublet J, Gaudissard J, Azizi M, et al. Endovascular ultrasound renal denervation to lower blood pressure in young hypertensive women planning pregnancy: study protocol for a multicentre randomised, blinded and sham controlled proof of concept study. BMJ Open. 2023;13:e071164.
pubmed: 37775290
pmcid: 10546167
doi: 10.1136/bmjopen-2022-071164
de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA, et al. Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up. Hypertension. 2017;69:836–43.
pubmed: 28320856
doi: 10.1161/HYPERTENSIONAHA.117.09086
Spiering W, Williams B, Van der Heyden J, van Kleef M, Lo R, Versmissen J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390:2655–61.
pubmed: 28870716
doi: 10.1016/S0140-6736(17)32337-1
Lobo MD, Ott C, Sobotka PA, Saxena M, Stanton A, Cockcroft JR, et al. Central iliac arteriovenous anastomosis for uncontrolled hypertension: one-year results from the ROX CONTROL HTN Trial. Hypertension. 2017;70:1099–105.
pubmed: 29061728
doi: 10.1161/HYPERTENSIONAHA.117.10142
Nakagami H, Ishihama T, Daikyoji Y, Sasakura C, Yamada E, Morishita R. Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. Hypertens Res. 2022;45:61–65.
pubmed: 34657138
doi: 10.1038/s41440-021-00755-6
Daemen J, Van Mieghem N. First-in-man radial access renal denervation with the ReCor Radiance catheter. EuroIntervention. 2015;10:1209–1212.
pubmed: 25493912
doi: 10.4244/EIJY14M12_03